Katarakt Cerrahisi Sonrası Endoftalmiyi Önlemede Ön Kamaraya Sefuroksim İle Moksifloksasin Uygulamasının Karşılaştırılması

Year 2020, Volume: 51 Issue: 4, 212 - 215, 15.12.2020

Gökhan Çelik , Hüseyin Sanisoğlu

https://doi.org/10.16948/zktipb.855520

Abstract

Amaç: Katarakt cerrahisi bitiminde ön kamaraya sefuroksim ve moksifloksasin verilen olguların ameliyat sonrası dönemde görme keskinliklerini (GK), göz içi basınç değerlerini (GB), endotel hücre sayılarını ve ön kamara hücre sayılarını değerlendirmek.
Metod: Çalışma kapsamında .......................................Eğitim ve Araştırma Hastanesi Göz Kliniği’nde Mart 2008-Mart 2009 tarihleri arasında katarakt cerrahisi gerçekleştirilen ve ameliyat sonrasında göz içerisine sefuroksim veya moksifloksasin verilen 42 hastanın 55 gözü değerlendirilmiştir. Hastaların ameliyat öncesi ve sonrası görme keskinlikleri , göz içi basınç değerleri , endotel hücre sayıları ve ön kamara hücre sayıları kaydedilmiştir.
Bulgular: Hastaların 20’si erkek 22’si kadındı. yaş ortalamaları 52.18±4.25 idi. Birinci ve İkinci grup hastaların yaş ort. sırasıyla 43.34±7.19 ve 60.1±4.72idi. Birinci grupta 21 hastanın 26 gözü, ikinci grupta 21 hastanın 29 gözü değerlendirildi. Her iki grupta yaş, takip süresi, ameliyat öncesi ve sonrası GK ve GİB değerleri, endotel hücre sayısı, ön kamara hücre miktarı ve takip süresi açısından istatistiksel olarak farklılık bulunmamıştır (p>0.05).
Sonuç: Endoftalmi profilaksisi için katarakt ameliyatı sonrası ön kamaraya sefuroksim ve moksifloksasin verilen hastalar arasında ameliyat sonrası GK, GİB, ön kamara hücre sayısı ve endoteli hücre sayıları açısından anlamlı fark gözlenmemiştir.

Keywords

Endoftalmi profilaksisi, katarakt cerrahisi, intrakamaral antibiyotik

References

• Referans1. Lindstrom R. Thoughts on cataract surgery. Review of Ophthalmology. 9 March 2015.
• Referans2. Srinivasan R, Gupta A, Kaliaperumal S, Babu RK, Thimmarayan SK, Belgode HN. Efficacy of intraoperative vancomycin in irrigating solutions on aqueous contamination during phacoemulsification. Indian J Ophthalmol. 2008;56(5):399-402.
• Referans3. Montan PG, Koranyi G, Setterquist HE, Stridh A, Philipson BT, Wiklund K. Endophthalmitis after cataract surgery: risk factors relating to technique and events of the operation and patient history: a retrospective case-control study. Ophthalmology. 1998;105(12):2171-7.
• Referans4. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. Journal of cataract and refractive surgery. 2007;33(6):978-88.
• Referans5. Beselga D, Campos A, Castro M, et al. Postcataract surgery endophthalmitis after introduction of the ESCRS protocol: a 5-year study. Eur J Ophthalmol 2013;24(4):516-9.
• Referans6. Galvis V, Tello A, Sánchez MA, Camacho PA. Cohort study of intracameral moxifloxacin in postoperative endophthalmitis prophylaxis. Ophthalmol Eye Dis 2014;6:1.
• Referans7. Haripriya A, Chang DF, Ravindran RD. Endophthalmitis reduction with intracameral moxifloxacin in eyes with and without surgical complications: Results from 2 million consecutive cataract surgeries. J Cat Ref Surg 2019;45(9):1226-1233.
• Referans8. Bowen RC, Zhou AX, Bondalapati S, et al. Comparative analysis of the safety and efficacy of intracameral cefuroxime, moxifloxacin and vancomycin at the end of cataract surgery: a meta-analysis. Br J Ophthalmol 2018 Jan 11.pii: bjophthalmol-2017-311051.
• Referans9. Srinivasan R, Gupta A, Kaliaperumal S, Babu RK, Thimmarayan SK, Belgode HN. Efficacy of intraoperative vancomycin in irrigating solutions on aqueous contamination during phacoemulsification. Indian J Ophthalmol. 2008;56(5):399-402.
• Referans10. Montan PG, Koranyi G, Setterquist HE, Stridh A, Philipson BT, Wiklund K. Endophthalmitis after cataract surgery: risk factors relating to technique and events of the operation and patient history: a retrospective case-control study. Ophthalmology. 1998;105(12):2171-7.
• Referans11. Mendivil Soto A, Mendivil MP. The effect of topical povidone-iodine, intraocular vancomycin, or both on aqueous humor cultures at the time of cataract surgery. American journal of ophthalmology. 2001;131(3):293-300.
• Referans12. Gimbel HV, Sun R, DeBrof BM. Prophylactic Intracameral Antibiotics During Cataract Surgery: The Incidence of Endophthalmitis and Corneal Endothelial Cell Loss. European journal of Implant and Refractive Surgery. 1994;6(5):280-5.
• Referans13. Schelonka L, SaBell M. Postcataract endophthalmitis prophylaxis using irrigation, incision hydration, and eye pressurization with vancomycin. Clinical Ophthalmology 2015;9:1337-45.
• Referans14. Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morbidity and mortality weekly report. 2002;51(26):565-7.
• Referans15. Relhan N, Albini TA, Pathengay A, Kuriyan AE, Miller D, Flynn HW. Endophthalmitis caused by Gram-positive organisms with reduced vancomycin susceptibility: literature review and options for treatment. Br J Ophthalmol 2015;100(4):446-52.
• Referans16. ASCRS-ASRS HORV Task Force members (2016) Clinical Alert: HORV Association with Intraocular Vancomycin. http://www.ascrs.org/sites/default/files/HORV-AlertFinal.pdf. Accessed 1st OCT 2017 . Referans17. Witkin AJ, Chang DF, Jumper JM, et al. Vancomycin-Associated Hemorrhagic Occlusive Retinal Vasculitis. Ophthalmology 2017;124(5):583-95.
• Referans18. Montan PG, Kornyi G, Philipson G: Postoperative endophthalmitis (POE) in relation to different surgical techniques in cataract extractions. A postoperative study. XIth. Congress Of The European Society Of Cataract And Refractive Surgeons. Abstract Book T-M111 6, Innsbruck 1993,82.
• Referans19. Montan PG, Wejde G, Setterquist H, Rylander M, Zetterström C. Prophylactic intracameral cefuroxime: evaluation of safety and kinetics in cataract surgery. J Cataract Refract Surg 2002;28(6):982-7.
• Referans20. McGee DH, Holt WF, Kastner PR, Rice RL. Safety of moxifloxacin as shown in animal and in vitro studies. Survey of ophthalmology. 2005;50 Suppl 1:S46-54.
• Referans21. Ritterband DC, Shah MK, Meskin SW, Shapiro DE, Seedor JA, Koplin RS, Hu DN, Shao S, Dahl P, McCormick S. Efficacy and safety of moxifloxacin as an additive in Optisol-GS a preservation medium for corneal donor tissue. Cornea 2006; 25:1084–9.
• Referans22. Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model. American journal of ophthalmology. 2005;140(3):497-504.
• Referans23. Lane Stephen S., Osher Robert H., Masket Samuel, Belani Shaleen. Evaluation of the safety of prophylactic intracameral moxifloxacin in cataract surgery .J Cataract Refract Surg 2008; 34:1451–9.
• Referans24. Espiritu Cesar Ramon G, Caparas Victor L, Bolinao Joanne G Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg 2007; 33:63–8.